A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs Anagrelide (Primary)
- Indications Essential thrombocythaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Shire
- 01 Nov 2018 Results of assessing long term safety and efficacy of Study 309, an extension Study 308, published in the International Journal of Hematology
- 02 May 2016 Primary endpoints updated due to which trial focus changed from AR to Tu and AR.
- 17 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.